ScaleReady announces a G-Rex® Grant has been awarded to ImmunoScape
"We are thankful for ScaleReady's G-Rex Grant Program and are grateful to receive an award that will substantially defray the time and cost of bringing our novel therapy into the clinic," said Dr.
"We are proud to award ImmunoScape a G-Rex Grant to facilitate the clinical readiness of their novel TCR-T cell therapy. Expediting the pathway to generating meaningful clinical data that their investors need to see is a primary objective of the G-Rex Grant Program. We are happy to see more private sector groups like ImmunoScape leveraging this unique program." said
As part of the G-Rex® Grant, ImmunoScape plans to complete their pre-clinical process development including the incorporation of
Additionally, ImmunoScape's G-Rex Grant will help facilitate the technology transfer of their G-Rex centric manufacturing process to their contract development and manufacturing organization (CDMO) partner. The G-
ScaleReady's G-Rex Grant Program is a
About ImmunoScape
ImmunoScape is a biotechnology company developing next-generation TCR-T cell therapies for the treatment of solid tumors. By leveraging Deep Immunomics and AI-driven insights, ImmunoScape is focused on identifying TCRs with superior therapeutic potential, selecting the best candidates for clinical development. With multiple programs in the discovery and preclinical stages, the company is performing IND-enabling studies and preparing for the lead program to enter into the clinic and exploring strategic partnerships that align with our mission to bring next-generation TCR-T therapies to more patients. For more information, please visit https://immunoscape.com/.
About ScaleReady
ScaleReady provides the field of cell and gene-modfied cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 4 commercially approved CGT drugs.
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing
About
Contact:
david.clair@bio-techne.com
612-656-4416
About
CellReady is the world's first and only G-Rex® centric contract development and manufacturing organization (CDMO) specializing in G-Rex® based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time.
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-immunoscape-302250120.html
SOURCE